Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
ALLO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.23 - $3.78
Previous CloseN/A
Volume1.66M
Average Volume (3M)3.37M
Market Cap
$310.69M
Enterprise Value$386.69M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Apr 30, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding217,264,740
10 Day Avg. Volume3,337,041
30 Day Avg. Volume3,372,297
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)15998.59
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit17.58K
Enterprise Value/Ebitda-1.56
Forecast
1Y Price Target
$8.50Price Target Upside507.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
---
Allogene Therapeutics News
See All ALLO News
---
Bulls Say, Bears Say
Bulls Say
Financial PositionAllogene ended 3Q24 with approximately $403.4M in cash and equivalents, which should support an operational runway extending into the second half of 2026.
Therapeutic PotentialCema-cel has the potential to leapfrog other autologous and allogeneic CD19 CAR-T therapies, remain competitive for longer, and expand the total addressable market.
Bears Say
Statistical ChallengesAchieving statistical significance in the ALPHA3 interim analysis may be challenging due to a relatively small alpha spend.
Trial UncertaintyThe futility analysis for ALPHA3 will focus on minimal residual disease conversion, and there is uncertainty on whether ALLO-647 will be part of the lymphodepletion regimen.
---
Ownership Overview
10.85% Insiders
21.78% Mutual Funds
0.83% Other Institutional Investors
58.45% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALLO FAQ
What was Allogene Therapeutics Inc’s price range in the past 12 months?
Allogene Therapeutics Inc lowest stock price was $1.23 and its highest was $3.78 in the past 12 months.
What is Allogene Therapeutics Inc’s market cap?
Allogene Therapeutics Inc’s market cap is $310.69M.
When is Allogene Therapeutics Inc’s upcoming earnings report date?
Allogene Therapeutics Inc’s upcoming earnings report date is Apr 30, 2025 which is in 13 days.
How were Allogene Therapeutics Inc’s earnings last quarter?
Allogene Therapeutics Inc released its earnings results on Mar 13, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.327 by $0.047.
Is Allogene Therapeutics Inc overvalued?
According to Wall Street analysts Allogene Therapeutics Inc’s price is currently Undervalued.
Does Allogene Therapeutics Inc pay dividends?
Allogene Therapeutics Inc does not currently pay dividends.
What is Allogene Therapeutics Inc’s EPS estimate?
Allogene Therapeutics Inc’s EPS estimate is -0.29.
How many shares outstanding does Allogene Therapeutics Inc have?
Allogene Therapeutics Inc has 217,264,740 shares outstanding.
What happened to Allogene Therapeutics Inc’s price movement after its last earnings report?
Allogene Therapeutics Inc reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.327. Following the earnings report the stock price went up 2.646%.
Which hedge fund is a major shareholder of Allogene Therapeutics Inc?
Currently, no hedge funds are holding shares in ALLO
---
Allogene Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (507.14% Upside)
$8.50 (507.14% Upside)
Blogger Sentiment
Bullish
ALLO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.87%
12-Months-Change
Fundamentals
Return on Equity
-55.13%
Trailing 12-Months
Asset Growth
-14.64%
Trailing 12-Months
Company Description
Allogene Therapeutics Inc
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
---
ALLO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with significant advancements in Allogene's CAR T programs, notably in large B cell lymphoma and autoimmune diseases. While there are financial losses and some strategic uncertainties, the overall sentiment is bolstered by strong trial progress and financial positioning.Read More>---
ALLO Stock 12 Month Forecast
Average Price Target
$8.50
▲(507.14% Upside)
Technical Analysis
Autolus Therapeutics
―
Annexon Biosciences
―
Compass Therapeutics
―
Sana Biotechnology
―
Zenas BioPharma, Inc.
―
Best Analysts Covering ALLO
1 Year
1 Year Success Rate
4/21 ratings generated profit
1 Year Average Return
-27.74%
reiterated a buy rating last month
Copying John Newman's trades and holding each position for 1 Year would result in 19.05% of your transactions generating a profit, with an average return of -27.74% per trade.
---